We have applied the criteria used for scoring of ERBB2 immunohistochemistry in breast cancer to obtain standardised assessment of expression and hence a more rational prediction of the proportion of bladder cancer patients who may benefit from ERBB2-targeted therapy. The gene discussed is ERBB2; the disease is urinary bladder carcinoma.